ASCO 2024: Research Roundup
Research being presented at ASCO 2024 is highlighting advances in hematologic, lung, breast, gastrointestinal, and other cancers.
Source: cancertherapyadvisor.com
Benjamin Solomon News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Benjamin Solomon. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Benjamin Solomon Today - Breaking & Trending Today
'Outstanding' 5 Year PFS With Lorlatinib in ALK+ NSCLC
Five-year follow-up data from the landmark CROWN trial shows significant progression-free survival in ALK+ NCSLC, but some experts question the use of crizotinib as the comparator drug.
Source: medscape.com
Pfizer's LORBRENA® CROWN Study Shows Majority of Patients with ALK-Positive Advanced Lung Cancer Living Beyond Five Years Without Disease Progression
An unprecedented 60% of patients remain alive without disease progression after five years Updated results show continued 81% reduction in risk of progression or death and 94% reduction in...
Source: marketscreener.com
Adjuvant Alectinib Could Aid Disease-Free Survival in ALK-Positive NSCLC
A 76% lower risk was displayed with adjuvant alectinib compared to chemotherapy treatment for non–small cell lung cancer.
Source: pharmacytimes.com
